Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
Pharming said it will make less money next year than people thought—about $30 million less. When a company lowers its money goals, it's a sign something changed, so pay attention to what they say about why.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.